While previous reviews have broadly examined VEGF/VEGFR signaling and therapeutic strategies in oncology [10,11,12,13], this review examines explicitly the distinct roles of VEGFR-1, -2, and -3 in PC, emphasizing their contributions to tumor progression, therapeutic resistance, and the limitations of VEGFR treatment in the most common forms of PC. This evidence concerns the gene FLT1 and neoplasm.